Monday, May 23, 2005 4:23:47 PM
Releasing Nanotech's Potential?
By Jack Uldrich
May 23, 2005
In February, pSivida (Nasdaq: PSDV), an Australian-based company specializing in biomedical applications of nanotechnology, began trading on the Nasdaq as an American Depositary Receipt (ADR). In its first three months on Wall Street, it promptly fell from a high of $10 a share to just over $4.
Since that time, however, pSivida's stock has risen by more than 65%. It currently trades at around $7.
Will it continue to rise? I believe so, and I base that answer on three recent developments. The first occurred in late April, when the company announced that its BrachySil technology had been granted its first patent in China. BrachySil is an experimental treatment for liver cancer that uses a biochip to release predetermined doses of radioactive molecules to kill cancer cells. Because China has the highest incidence of liver cancer in the world, the patent could yield significant dividends -- provided the technology proves effective.
In the United States, the company is currently awaiting approval on BrachySil from the Food and Drug Administration, but the preliminary results been very promising.
The second positive development occurred last week, when pSivida reported that Jorg Schreiber, a former executive for Roche Diagnostics, has joined the board of directors at AION Diagnostics, one of pSivida's subsidiaries. Schreiber, a former vice president of R&D with Roche, has a great deal of experience in diagnostic-product development -- experience that could prove helpful in commercializing pSivida's BioSilicon technology.
BioSilicon is silicon manufactured with "nanopores" that can be loaded with drugs, genes, proteins, and other therapeutics or vaccines. It could prove useful in everything from drug delivery and brachytherapy to tissue engineering.
The third and most recent development -- as well as the most significant one -- happened on May 18, when pSivida announced that BioSilicon had delivered excellent results in releasing Melontan, a drug that stimulates the production of melanin and causes skin to tan without being exposed to any harmful UV rays. That news offered tangible proof that BioSilicon is capable of releasing a drug over a sustained period of time, and it bolsters the company's claim that BioSilicon could become a preferred delivery platform for a number of drugs.
So do these separate announcements suggest that pSivida has turned the corner? No, but the company is clearly moving in the right direction. It was an attractive stock at $10 a share, and I think it is even more attractive at $7.
A near-term upside could come if the still-secret Big Pharma company currently testing the BioSilicon technology announces positive results.
However, pSivida is the sort of stock that makes many an investor shiver. The company is not expecting profitability until 2008. It's a very risky investment for that reason, as well as for many others, including currency fluctuations, the firm's thinly traded nature, and the inherent uncertainty over FDA approval of BioSilicon.
This is also a very small company -- pSivida's market cap is $120 million. Tiny stocks carry big risks, including a predisposition to volatility. If you want to invest, tread carefully; limit orders are always a good idea in micro-cap land.
Recent EYPT News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 09:04:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 09:03:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 09:00:10 PM
- EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024 • GlobeNewswire Inc. • 06/26/2024 12:00:00 PM
- EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024 • GlobeNewswire Inc. • 06/18/2024 11:00:00 AM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/17/2024 11:00:00 AM
- EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference • GlobeNewswire Inc. • 06/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 11:05:42 AM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/16/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 02:12:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 08:23:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:11 AM
- EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:25:17 PM
- EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy • GlobeNewswire Inc. • 05/06/2024 11:00:00 AM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 11:00:00 AM
- EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/18/2024 11:00:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/08/2024 06:53:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:05:09 PM
- EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:40:53 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:37:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:01:44 PM
- EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM